Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CEL-SCI Corporation (NYSE American: CVM) SEC filings, offering detailed insight into the company’s clinical stage cancer immunotherapy business and capital structure. As a Colorado corporation filing under Commission file number 001-11889, CEL-SCI uses periodic and current reports to describe its development of Multikine (Leukocyte Interleukin, Injection), financing activities, and corporate governance arrangements.
Investors can review Form 10-K and Form 10-Q filings for discussions of research and development expenses, going concern disclosures, and updates on the Multikine clinical program in head and neck cancer. These reports typically describe the company’s strategy of boosting the immune system before surgery, radiotherapy and chemotherapy have damaged it, and summarize the status of the completed Phase 3 study and planned 212-patient confirmatory Registration Study.
Form 8-K current reports are particularly important for CEL-SCI. Recent 8-K filings disclose material definitive agreements for best-efforts public offerings of common stock with ThinkEquity LLC as placement agent, including the number of shares issued, offering prices, gross proceeds, and intended use of proceeds to fund the continued development of Multikine, general corporate purposes, and working capital. Other 8-Ks report amendments and revisions to the company’s Shareholder Rights Agreement, including extensions of its expiration date and related governance terms.
Users can also reference registration statements on Form S-3 cited in these filings, which support CEL-SCI’s shelf offerings. Together, these documents help clarify how the company finances its operations, manages shareholder rights, and describes the risks associated with its clinical stage status, including going concern language noted by its independent auditors. Stock Titan’s tools can surface the most relevant sections, summarize lengthy filings, and make it easier to track new CVM filings as they are posted to EDGAR, including any future Forms 4 reporting insider transactions.
CEL-SCI Corporation reported another loss-making quarter and reiterated serious liquidity risks. For the three months ended December 31, 2025, the company recorded a net loss of about
Cash and cash equivalents fell to roughly
The company remains focused on its lead cancer immunotherapy, Multikine, which in a prior Phase III study showed a five‑year survival rate of 73% in a defined head and neck cancer target population versus 45% in controls and a hazard ratio of 0.35. CEL-SCI plans a 212‑patient confirmatory registration study, estimated to cost
CEL-SCI Corp's Chief Executive Officer and director Geert Kersten purchased 38,023 shares of the company’s common stock on January 22, 2026 at
According to the filing, these were shares of restricted stock bought directly from the company at the closing price on January 21, 2026, which was the most recent closing price available. After this transaction, Kersten directly owns 120,815 shares of CEL-SCI common stock.
CEL-SCI Corporation's Chief Scientific Officer, Eyal Talor, reported a small open-market purchase of company stock. On 12/31/2025, he acquired 456 shares of common stock at a price of $5.26 per share. Following this transaction, he beneficially owns 6,264 shares of CEL-SCI common stock in direct ownership. This filing reflects personal share accumulation by a senior officer rather than a company-level financing or business event.
CEL-SCI Corporation's Chief Financial Officer, Patricia Prichep, reported acquiring additional common stock in the company. On 12/31/2025, she acquired 815 shares of CEL-SCI common stock at a price of $5.26 per share. Following this transaction, she beneficially owned 12,028 shares of CEL-SCI common stock in direct ownership. This insider transaction reflects a modest increase in the CFO’s personal stake in the company.
CEL-SCI Corp insider activity: Chief Executive Officer and Director Geert Kersten reported acquiring 998 shares of CEL-SCI common stock on 12/31/2025 at a price of $5.26 per share. Following this transaction, he beneficially owns 82,792 shares held directly.
CEL-SCI Corporation files its annual report describing late‑stage development of its lead cancer immunotherapy Multikine and its financial position. In a Phase 3 study target population, Multikine‑treated head and neck cancer patients showed a 5‑year survival of 73% versus 45% for controls, with a hazard ratio of 0.35 and supportive bias analyses. Regulators have allowed CEL-SCI to move forward with a 212‑patient confirmatory registration study, which the company estimates will cost about $30 million. CEL-SCI reports cumulative net losses of approximately $539 million through September 30, 2025 and cash and cash equivalents of about $11.0 million, and acknowledges substantial doubt about its ability to continue as a going concern without new capital. A 1‑for‑30 reverse stock split became effective in May 2025, and as of December 19, 2025 the company had 8,408,746 common shares outstanding.
CEL-SCI Corp (CVM) reported an insider stock purchase by its Chief Executive Officer and director, Geert Kersten. On December 4, 2025, Kersten bought 8,389 shares of CEL-SCI common stock in an open market-style transaction coded as a purchase. The filing reports a purchase price of $5.96 per share, matching the company’s closing price on December 3, 2025, which the company used as the most recent closing price available.
Following this transaction, Kersten beneficially owns 81,794 shares of CEL-SCI common stock directly. The filing is made on Form 4, which discloses changes in ownership by company insiders such as directors and executive officers.
CEL-SCI Corporation filed a Form 8-K to report that its Board of Directors approved revisions to the company’s Shareholder Rights Agreement on
CEL-SCI Corporation filed a resale registration on Form S-3 covering up to 375,000 shares of common stock previously issued to Ergomed Group Limited for services tied to the confirmatory Phase III trial. This is a secondary offering by the selling shareholder; CEL-SCI will not receive any proceeds from share sales.
The shares may be sold from time to time through various methods described in the plan of distribution. Ergomed has agreed not to sell more than 2,000 shares per day without CEL-SCI’s consent. As context, 8,016,035 shares were outstanding as of November 6, 2025. CEL-SCI’s common stock trades on NYSE American under “CVM,” and the closing price on November 6, 2025 was $6.64 per share.
The prospectus highlights risks typical of clinical-stage biopharma, including substantial doubt about the company’s ability to continue as a going concern, and material weaknesses in internal control over financial reporting.
CEL-SCI Corporation amended its Shareholder Rights Agreement, setting a new expiration of October 30, 2030. The agreement was originally adopted on November 7, 2007. The company filed the amended agreement as an exhibit and referenced the summary in its prior Form S-3 under “Description of Securities - Rights Agreement.”